Carag receives US FDA IDE approval to conduct clinical study of first transcatheter septal occluder with bioresorbable, metal-free framework
The CE-marked CBSO is the first-ever transcatheter septal occluder with bioresorbable, metal-free framework. Carag's first U.S. trial is…